31 July 1995 00:00 [Source: ICB]
GLAXO WELLCOME'S continuing post-takeover review has so far claimed nearly 1300 job casualties among staff in France and the US.
A rationalization plan disclosed to French trade unions includes the loss of 267 jobs out of the group's 2475 work-force in France.
The jobs affected will be mainly in administration and sales, partly resulting from the closure of one of the two Paris headquarter buildings, the company said, although individual staff have not yet been selected. The redundancies are expected to take effect around the end of the year.
Measures taken to reduce the total tally of job losses in France include a reduction in working hours for remaining staff from 39h/week to 37 in/week with full salary maintained.
Meanwhile, Glaxo has announced the loss of 1000 of 1350 jobs at the former Wellcome drugs manufacturing facility in Greenville, North Carolina.
Prescription medicine manufacturing will be transferred to the Zebulon, North Carolina, plant, although otc products will continue to be produced at Greenville for the foreseeable future, the company said.
The worldwide review is likely to produce further job losses in other territories, Glaxo indicated.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Sample issue >>
My Account/Renew >>
Register for online access >>
|ICIS Top 100 Chemical Companies|
|Download the listing here >>|